VITRAKVI (larotrectinib) capsules
Vitrakvi is a cancer medicine for treating solid tumours with NTRK gene fusion. NTRK gene fusion is a rare genetic abnormality that can occur in tumours from different parts of the body such as the lungs, thyroid glands and intestines.Brand Name: VITRAKVI (larotrectinib) capsules, for oral use, VITRAKVI® (larotrectinib) oral solution Initial U.S. Approval: 2018
Home | larotrectinib capsules
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
Call / WhatsApp Number
+91 9289711088 (Ms. Laxmi Singh)
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
VITRAKVI (larotrectinib) capsules, for oral use
Larotrectinib sulfate is approved to treat: Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins.
VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:
• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
• are metastatic or where surgical resection is likely to result in severe morbidity, and
• have no satisfactory alternative treatments or that have progressed following treatment.
Larotrectinib is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is “tissue agnostic”). Larotrectinib was approved for medical use in the European Union in September 2019.[16][17] It was approved for medical use in Australia in August 2020.
Drug (Brand / Generic): VITRAKVI / larotrectinib
Current Indications: solid tumours with NTRK gene fusion
Marketed by:: Bayer HealthCare
Approval Date: 2018
Capsules: 25 mg, 100 mg, Oral Solution: 20 mg/mL.
For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here
Alleviare Life Sciences
About Us
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “VITRAKVI (larotrectinib) capsules”.
Confirmation of the order for VITRAKVI (larotrectinib) capsules will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha
ALS serves as a facilitator, supplier & exporter in India assisting patients, doctors, and hospitals in importing the prescription medicine brand VITRAKVI (larotrectinib) capsules. The import process requires a valid prescription and an Import License in the Patient’s Name.
For patients from following foreign countries seeking access to VITRAKVI (larotrectinib) capsules, they can inquire and find further information by sending their inquiries to ALS.
We have delivered medicines to following countries – Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, India, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe.
Kindly reach out to us for VITRAKVI (larotrectinib) capsules price and availability confirmation.
The price of the medicines is the cost set by the manufacturer. In addition, Named Patient support fee, shipping costs and any local tax (if applicable) will apply.
